ClinicalTrials.gg
Sign In
RecruitingNCT05882773Updated May 31, 2023

Asian Myeloproliferative Neoplasm (MPN) Registry

An observational study in Myeloproliferative Neoplasm, Polycythemia Vera and Essential Thrombocythemia, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by The University of Hong Kong · Observational

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Study summary

This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.

Read the detailed description

This is a multinational, multicenter, prospective and retrospective, observational, cohort registry of patients with MPN. The registry mainly involves study centres in Asia including but not limited to Hong Kong, Singapore, Malaysia, Taiwan, Korea and Thailand. Clinicopathologic characteristics, cytogenetic characteristics, mutational characteristics, treatment characteristics, outcomes and survivals of Asian patients MPN diagnosed between 2010-2025 will be collected to establish clinical registry.

Data on the clinicopathologic characteristics, cytogenetics, mutational profile, prognostic scoring treatment characteristics, responses to treatment, outcome and survivals will be collected through routine clinic visits and/or reviewing medical records. Data will be collected at diagnosis, and approximately every 6 months thereafter (for prospective data) and at progression until death/study termination.

02

Conditions studied

  • Myeloproliferative Neoplasm
  • Polycythemia Vera
  • Essential Thrombocythemia
  • Post-polycythemia Vera Myelofibrosis
  • Post-essential Thrombocythemia Myelofibrosis
  • Primary Myelofibrosis
  • Primary Myelofibrosis, Prefibrotic Stage
  • Primary Myelofibrosis, Fibrotic Stage

Keywords

  • Myeloproliferative neoplasm
  • Epidemiology
  • Outcome
  • Prognostic factors
03

In context

Myeloproliferative Disorders

667 studies on the registry are indexed under Myeloproliferative Disorders; 110 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 150 across 115 observational studies indexed under Myeloproliferative Disorders.

Browse Myeloproliferative Disorders studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,292 studies on the registry; 348 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Browse The University of Hong Kong studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Three study cohorts will be involved in the study. They are:

Prospective cohort - Subjects will be enrolled in the study at their diagnosis of MPN. All data will be collected on-study prospectively.

Partial prospective/retrospective cohort (partial-P/R) - Subjects will be enrolled in the study after they have been diagnosed of MPN for a period of time and still being followed up clinically (alive). Data from study enrollment forward will be collected prospectively at around 6-month intervals on-study. Data prior to study enrollment are the events of interest happened and will be collected retrospectively.

Retrospective cohort - Subjects enrolled in the study after they were diagnosed of MPN and died/lost to follow. All data will be collected retrospectively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old at the time of diagnosis of MPN.

  2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):

    1. Polycythaemia vera
    2. Essential thrombocythemia
    3. Primary myelofibrosis, pre-fibrotic/early stage
    4. Primary myelofibrosis, overt fibrotic stage
    5. Post-polycythaemia vera myelofibrosis
    6. Post-essential thrombocythaemia myelofibrosis
    7. MPN-unclassifiable
  3. All subjects need to provide .

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible if he/she meets any of the following criteria:

  1. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
1,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Time to progression to secondary myelofibrosis (for PV and ET)

    Measured in months, from date of diagnosis of MPN to date of documentation of secondary myelofibrosis (event), death (event) or latest follow-up (censor). Patient without an event will be censored at date last known to be progression-free

    Time frame: 10 years

  2. Progression-free survival (PFS)

    Measured in months, from date of diagnosis of MPN to the date of the first MDS or AML or death due to any cause. Patient without an event will be censored at date last known to be progression-free and alive.

    Time frame: 10 years

  3. Overall survival (OS)

    Measured in months from the date of diagnosis of MDS until the date of death due to any cause. Patient who is alive will be censored at the date last known alive

    Time frame: 10 years

07

Study locations

1 of 1 sites recruiting
  • Department of Medicine, Queen Mary Hospital
    Hong Kong, Hong Kong
    Recruiting
    • Harinder Gill, MD · Contactgillhsh@hku.hk · +852 22554542
    • Harinder Gill, MD · Principal investigator
    • Garret Leung, MD · Sub investigator
    • Yok-lam Kwong, MD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2023; primary completion for May 2026, 36 months later.

Of 37 observational studies under Myeloproliferative Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 62. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2023
First posted
May 31, 2023
StartEst.
May 2023
Primary completionEst.
May 2026
CompletionEst.
Dec 2026
Last update
May 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05882773
Lead sponsor
The University of Hong Kong
Collaborators
Novartis
Responsible party
Sponsor
First posted
May 31, 2023
Start date
May 2023 (estimated)
Primary completion
May 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 31, 2023

Study contacts

Harinder Gill, MD
Contact
gillhsh@hku.hk
+852 22554542
Harinder Gill, MD
principal investigator · The University of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Myeloproliferative Disorders →

Other studies from this sponsor

The University of Hong Kong →

Start the discussion